The Kiwi partnership financing Parkinson’s breakthrough

Sections Latest News All Latest News News in Brief Hot Topics All Hot Topics Earnings 2026 Election 2026 Fuel Fallout Wellness, Inc Markets All Markets Earnings Market Close Small Cap Wrap Opinion All Opinion On the Money Self Promotion Companies All Companies Business Advice CEO Index Hospitality Media Not For Profit Retail Services Startups Tourism Transport Economy All Economy Health Māori Economy Sport Trade Trump Tariffs Energy All Energy Energy Crunch Finance All Finance Sustainable Finance Government All Government Business of Government Environment Immigration Law and Regulations Policy Climate Change Politics Budget 2026 Public Sector Infrastructure Investigations All Investigations Business of Education Business of Food Business of Health Business of Housing Blue Highway Productivity Unleashed Risky Business Investments All Investments Kiwisaver Stock & Trade Primary Sector All Primary Sector Fishing Agriculture Dairy Farming Property All Property Du Val Technology All Technology Cryptocurrency Podcasts Business of Tech The Life All The Life Autos Culture Executive Health Fashion Gadgets Home of the Month Luxury Travel My Expat Life Road to Retirement Table & Glass The Collector The Edit The Life of...

Vitality World Business Working Well Sponsored Stories More Video Quizzes BusinessDesk About us Subscribe Manage Your Subscriptions ‌ The Nasdaq Tower celebrated Ceravance's latest Parkinson's results. Photo / Cerevance The Nasdaq Tower celebrated Ceravance's latest Parkinson's results.

Photo / Cerevance A quiet Kiwi partnership is behind a massive Parkinson’s breakthrough drug making headlines around the world. Wellington-based MQB Partners, whose directors include Infratil former chief executive Marko Bogoievski , has backed Cerevance since 2024. Boston-based Cerevance earlier this year closed an oversubscribed US$20 million (NZ$35.4m) TOP